Antiviral treatment in patients with cytomegalovirus positive ulcerative colitis

Table 1 Clinical and demographic characteristics of the included patients (mean ± SD)

Patient characteristic	Treated (n = 7)	Untreated (n = 6)	P value
Age (yr)	50.0 ± 14.6	45.0 ± 13.6	0.540
Gender (male/female)	4/3	3/3	0.400
Extent of disease
Pancolitis	6	5	0.540
Left-sided	1	1	0.540
Age at diagnosis of UC, yr	35.7 ± 13.3	41.5 ± 13.3	0.530
Duration of disease, yr	14.2 ± 9.3	3.5 ± 1.8	0.008
Hospitalized patients	6	4	0.560
Prehospitalization treatment
SC	4	2	0.560
Thiopurines	3	2	1.000
Infliximab	11	0	1.000
5-asa	5	4	1.000
SC + thiopurines	2	1	1.000
Treatment during hospitalization
SC	6	3	0.400
Infliximab	1	0	1.000
Cyclosporine	3	0	0.200
Timing of colonoscopy (d)	3.8 ± 2.4	2.7 ± 3.4	0.600
Positive cytopathic changes on HE staining	2	0	0.460
Hospitalization outcome
Death	1	0	1.000
Colectomy	1	0	1.000
Outcome by the end of the follow-up
Colectomy	3	0	0.190
Death	1	0	1.000

¹Combined with systemic corticosteroids and thiopurine. Treated: Patients who received antiviral therapy; Untreated: Patients who did not receive antiviral therapy; Timing of colonoscopy: Number of days from hospital admission; SC: Systemic corticosteroids; HE: Hematoxylin and eosin; IHC: Immunohistochemistry; UC: Ulcerative colitis.